MXPA03004394A - Profarmacos de cianoguanidina. - Google Patents
Profarmacos de cianoguanidina.Info
- Publication number
- MXPA03004394A MXPA03004394A MXPA03004394A MXPA03004394A MXPA03004394A MX PA03004394 A MXPA03004394 A MX PA03004394A MX PA03004394 A MXPA03004394 A MX PA03004394A MX PA03004394 A MXPA03004394 A MX PA03004394A MX PA03004394 A MXPA03004394 A MX PA03004394A
- Authority
- MX
- Mexico
- Prior art keywords
- optionally substituted
- branched
- straight
- halogen
- hydrocarbon radical
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 title 1
- -1 nitro, amino, cyano, aminosulfonyl Chemical group 0.000 abstract 19
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 239000004215 Carbon black (E152) Substances 0.000 abstract 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 229930195733 hydrocarbon Natural products 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 229910020008 S(O) Inorganic materials 0.000 abstract 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- 229910002651 NO3 Inorganic materials 0.000 abstract 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25207800P | 2000-11-21 | 2000-11-21 | |
| PCT/DK2001/000750 WO2002042265A2 (en) | 2000-11-21 | 2001-11-14 | Cyanoguanidine prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03004394A true MXPA03004394A (es) | 2004-04-20 |
Family
ID=22954502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03004394A MXPA03004394A (es) | 2000-11-21 | 2001-11-14 | Profarmacos de cianoguanidina. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6525077B2 (https=) |
| EP (2) | EP1339686B1 (https=) |
| JP (1) | JP4521157B2 (https=) |
| KR (1) | KR100871577B1 (https=) |
| CN (1) | CN100368401C (https=) |
| AU (3) | AU1494702A (https=) |
| BR (1) | BR0115514A (https=) |
| CA (1) | CA2426601C (https=) |
| CZ (1) | CZ305764B6 (https=) |
| ES (2) | ES2643083T3 (https=) |
| HU (1) | HU230544B1 (https=) |
| IL (2) | IL155483A0 (https=) |
| MX (1) | MXPA03004394A (https=) |
| PL (1) | PL224371B1 (https=) |
| RU (1) | RU2312858C2 (https=) |
| WO (2) | WO2002042265A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711123D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| US20030045515A1 (en) * | 2001-05-24 | 2003-03-06 | Lise Binderup | Combination medicament for treatment of neoplastic diseases |
| US7253193B2 (en) | 2002-05-17 | 2007-08-07 | Leo Pharma A/S | Cyanoguanidine prodrugs |
| CA2485351C (en) * | 2002-05-17 | 2011-12-06 | Leo Pharma A/S | Cyanoguanidine prodrugs |
| BR0309988A (pt) * | 2002-05-17 | 2005-02-22 | Leo Pharma As | Composto, composição farmacêutica, métodos para tratar ou melhorar doenças ou condições proliferativas e doenças inflamatórias, e, uso de um composto |
| US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
| AU2004228668B2 (en) * | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
| ES2572777T3 (es) | 2004-12-22 | 2016-06-02 | Leo Pharma A/S | Compuestos novedosos de cianoguanidina |
| EP1917244A2 (de) | 2005-08-24 | 2008-05-07 | Abbott GmbH & Co. KG | Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
| WO2009072004A2 (en) * | 2007-09-26 | 2009-06-11 | Gemin X Pharmaceuticals Canada, Inc. | Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
| US8173677B2 (en) * | 2007-09-26 | 2012-05-08 | Gemin X Pharmaceuticals Canada Inc. | Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
| US8101606B2 (en) | 2007-11-12 | 2012-01-24 | Washington University | Neurofibromin pathway modulators |
| RU2011111728A (ru) | 2008-08-29 | 2012-10-10 | Топотаргет А/С (Dk) | Новые производные мочевины и тиомочевины |
| CA2751495C (en) | 2009-02-06 | 2013-08-20 | Tianjin Hemay Bio-Tech Co., Ltd. | Pharmaceutical compositions comprising a pyridyl cyanoguanidine and cyclodextrin and/or derivatives thereof |
| CA2768338A1 (en) | 2009-07-17 | 2011-01-20 | Topotarget A/S | Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors |
| US9224007B2 (en) * | 2009-09-15 | 2015-12-29 | International Business Machines Corporation | Search engine with privacy protection |
| US9600134B2 (en) | 2009-12-29 | 2017-03-21 | International Business Machines Corporation | Selecting portions of computer-accessible documents for post-selection processing |
| US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
| WO2011121055A1 (en) | 2010-03-31 | 2011-10-06 | Topotarget A/S | Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety |
| AR082886A1 (es) | 2010-09-03 | 2013-01-16 | Forma Therapeutics Inc | Compuestos y composiciones farmaceuticas que los contienen |
| WO2012137225A1 (en) * | 2011-04-08 | 2012-10-11 | Sphaera Pharma Pvt. Ltd | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds |
| US9195853B2 (en) | 2012-01-15 | 2015-11-24 | International Business Machines Corporation | Automated document redaction |
| CN106905297A (zh) * | 2012-06-15 | 2017-06-30 | 加利福尼亚大学董事会 | 用于脑癌的新颖治疗剂 |
| JP2015522028A (ja) * | 2012-06-27 | 2015-08-03 | アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッドＡｌｚｈｅｉｍｅｒ’Ｓ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ａｍｅｒｉｃａ， Ｉｎｃ． | 化合物とその治療用途 |
| AU2013326850B2 (en) * | 2012-10-04 | 2017-09-21 | Inhibikase Therapeutics, Inc. | Novel compounds, their preparation and their uses |
| US9892278B2 (en) | 2012-11-14 | 2018-02-13 | International Business Machines Corporation | Focused personal identifying information redaction |
| US10227333B2 (en) | 2015-02-11 | 2019-03-12 | Curtana Pharmaceuticals, Inc. | Inhibition of OLIG2 activity |
| MX394452B (es) | 2015-02-27 | 2025-03-21 | Curtana Pharmaceuticals Inc | Inhibicion de la actividad de olig2. |
| WO2017162536A1 (en) | 2016-03-21 | 2017-09-28 | H. Lundbeck A/S | Vortioxetine prodrugs |
| US20200138964A1 (en) * | 2017-04-25 | 2020-05-07 | Seikagaku Corporation | Tertiary amine compound or imine compound-polymer conjugate and production method therefor |
| EP3590927A1 (en) * | 2018-07-05 | 2020-01-08 | Bayer Animal Health GmbH | Novel compounds for controlling arthropods |
| US11174229B2 (en) | 2018-10-29 | 2021-11-16 | Kempharm, Inc. | D-amphetamine compounds, compositions, and processes for making and using the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5938390A (en) * | 1989-06-26 | 1991-01-17 | Research Foundation Of The State University Of New York, The | Bis-acyloxymethyl derivatives |
| GB9219472D0 (en) | 1992-09-15 | 1992-10-28 | Leo Pharm Prod Ltd | Chemical compounds |
| GB9607219D0 (en) * | 1996-04-04 | 1996-06-12 | Smithkline Beecham Plc | Novel compounds |
| GB9711124D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711119D0 (en) | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711125D0 (en) | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711123D0 (en) | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| WO2000061561A1 (en) * | 1999-04-09 | 2000-10-19 | Shionogi Bioresearch Corp. | Cyanoguanidine compounds |
| WO2000061559A1 (en) * | 1999-04-09 | 2000-10-19 | Shionogi Bioresearch Corp. | N-substituted cyanoguanidine compounds |
-
2001
- 2001-11-12 AU AU1494702A patent/AU1494702A/xx active Pending
- 2001-11-14 ES ES15150976.7T patent/ES2643083T3/es not_active Expired - Lifetime
- 2001-11-14 CA CA2426601A patent/CA2426601C/en not_active Expired - Lifetime
- 2001-11-14 ES ES01983436.5T patent/ES2549260T3/es not_active Expired - Lifetime
- 2001-11-14 EP EP01983436.5A patent/EP1339686B1/en not_active Expired - Lifetime
- 2001-11-14 KR KR1020037006880A patent/KR100871577B1/ko not_active Expired - Lifetime
- 2001-11-14 HU HU0400564A patent/HU230544B1/hu unknown
- 2001-11-14 WO PCT/DK2001/000750 patent/WO2002042265A2/en not_active Ceased
- 2001-11-14 CZ CZ2003-1303A patent/CZ305764B6/cs not_active IP Right Cessation
- 2001-11-14 PL PL362864A patent/PL224371B1/pl unknown
- 2001-11-14 CN CNB018192440A patent/CN100368401C/zh not_active Expired - Lifetime
- 2001-11-14 JP JP2002544401A patent/JP4521157B2/ja not_active Expired - Lifetime
- 2001-11-14 MX MXPA03004394A patent/MXPA03004394A/es active IP Right Grant
- 2001-11-14 IL IL15548301A patent/IL155483A0/xx unknown
- 2001-11-14 BR BR0115514-8A patent/BR0115514A/pt not_active Application Discontinuation
- 2001-11-14 EP EP15150976.7A patent/EP2894149B1/en not_active Expired - Lifetime
- 2001-11-14 AU AU2002214947A patent/AU2002214947B2/en not_active Expired
- 2001-11-14 RU RU2003118446/04A patent/RU2312858C2/ru active
- 2001-11-20 AU AU2002223511A patent/AU2002223511A1/en not_active Abandoned
- 2001-11-20 WO PCT/DK2001/000770 patent/WO2002042276A1/en not_active Ceased
- 2001-11-20 US US09/988,819 patent/US6525077B2/en not_active Expired - Lifetime
-
2003
- 2003-04-15 IL IL155483A patent/IL155483A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03004394A (es) | Profarmacos de cianoguanidina. | |
| WO2022235935A3 (en) | Ionizable cationic lipids for rna delivery | |
| PE20251288A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| NZ324007A (en) | Quinazoline derivatives susbtituted by a phenyl and medicaments | |
| BR0111377A (pt) | Derivados de tiofeno úteis como agentes anticancerìgenos | |
| ATE345336T1 (de) | Benzothiepine als ileal bile acid transport inhibotoren | |
| BRPI0409938A (pt) | derivados de azetidinacarboxamida e seu uso em terapia | |
| HRP20080113T3 (hr) | Supstituirani piridinilni i pirimidinilni derivati kao modulatori metabolizma i liječenje bolesti koje su s tim povezane | |
| PH12021551257A1 (en) | Cyclic pantetheine derivatives and uses thereof | |
| MY133473A (en) | Haterocyclic glycyl beta-alanine derivatives. | |
| NO20052802L (no) | Pyrrolopyrimidinderivativer | |
| EA200100600A3 (ru) | Новые соединения дифенилмочевины, способ их получения и содержащие их фармацевтические композиции | |
| MY139446A (en) | Novel quinoline derivatives | |
| ATE363473T1 (de) | Substituierte pyrazoloverbindungen zur behandlung von entzündungen | |
| DE60233656D1 (de) | Pyridylcyanoguanidin verbindungen | |
| BR9811521A (pt) | Composição para tratar ou impedir a glomerulopatia | |
| CY1111909T1 (el) | Παραγωγα [[2-(αμινο-3,4-διοξο-1-κυκλοβουτεν-1-υλ)amino] αλκυλ]-οξεος για τη θεραπεια του πονου | |
| MY141583A (en) | Novel fused heterocycles and uses thereof | |
| TR200101711T2 (tr) | Antihistaminik spiro bileşikler. | |
| MY141579A (en) | Pyrrolidine-2-one derivatives, processes for their preparation, composition containing them and their use as factor xa inhibitors | |
| MY122147A (en) | Water soluble azoles as broad-spectrum antifungals | |
| MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
| MXPA06001039A (es) | Derivados de nicotinamida utiles como inhibidores de pde4. | |
| BR0313000A (pt) | Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente | |
| AR029913A1 (es) | Un compuesto derivado de p-(sulfonil)-aril y -heteroaril amina, su uso, y una composicion farmaceutica que lo comprende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |